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Abstract
Background: Vascular smooth muscle cell migration and accumulation in response to growth factors extensively
contribute to the development of intimal thickening within the vessel wall. Cumulative evidence has shown that
actin cytoskeleton polymerization and rearrangement are critical steps during cellular spreading and migration.
Integrin-linked kinase, an intracellular serine/threonine kinase, is a cytoplasmic interactor of integrin beta-1 and
beta-3 receptors regulating cell-cell and/or cell-extracellular matrix interaction, cell contraction, extracellular matrix
modification, and cell spreading and migration in response to various stimuli. However, the regulatory role of ILK
during vascular smooth muscle cell migration and the importance of integrin signaling in occlusive vascular
diseases are not yet fully elucidated.
Results: In the present study, we report that integrin-linked kinase controls mouse aortic smooth muscle cell
migration in response to platelet-derived growth factor. We have also identified p38 mitogen activated protein
kinase as a downstream signaling pathway of the integrin-linked kinase that regulates platelet-derived growth
factor-induced actin polymerization and smooth muscle cell migration.
Conclusion: This study will provide new insights into the potential therapeutic value of modulating integrin
signaling in an attempt to block or delay smooth muscle cell migration and the progression of vascular diseases.
Background
The initiation and progression of intimal thickening in
arterial walls is largely due to migration and subsequent
proliferation of smooth muscle cells (SMCs) in the sub-
intimal space in response to various stimuli including
oxidized low density lipoprotein (oxLDL), circulating
growth factors, and inflammatory cytokines such as pla-
telet-derived growth factor (PDGF), tumor necrosis fac-
tor (TNF)-a, and interleukin-1 (IL-1) [1,2]. Of these,
PDGF, a growth factor released by vascular SMC,
endothelial cells, and platelets, has been reported as the
most potent inducer of SMC migration within the
injured area of the vascular wall.
PDGF is a heparin-binding growth factor composed of
polypeptide chains that can be assembled into homodi-
mers (PDGF-AA, -BB) or heterodimer (PDGF-AB)
structures and bind to two related cell-surface receptors
with tyrosine kinase activity, PDGF receptor a and b
[3-5]. In the last few years two additional homodimers
PDGF-CC and PDGF-DD were also discovered [6-9].
PDGF binding to its cognate receptors results in dimeri-
zation, and subsequent auto-phosphorylation of specific
tyrosine residues outside the kinase domain, creating a
docking site for SH2 domain-containing signaling pro-
teins. A large number of SH2 domain containing pro-
teins including the phsophatidylinositol-3 kinase (PI3K),
phospholipase C-g (PLC-g), the tyrosine phosphatase
SHP-2, Ras GTPase activating protein (Ras-GAP), Grb2,
Grb7, Nck, and the Src family of tyrosine kinases have
been shown to bind to cytoplasmic tails of PDGF recep-
tors activating various downstream signaling proteins
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migration [10].
Cellular migration is regulated via a complex interac-
tion between growth factors that attach to their cognate
receptors, transmembrane integrins that bind to the
components of extracellular matrix, and mechanical
stress, all of which cooperatively induce polymerization
and reorganization of the actin cytoskeleton. These
events are coordinated by mechanisms involved in
assembly or disassembly of local adhesion sites, transient
changes in actin filaments dynamics, and formation of
discrete structures such as stress actin fibers, membrane
ruffles, lamellipodia, and filopodia [11-13]. Integrin-
linked kinase (ILK), a serine-threonine protein kinase
containing a catalytic domain at C terminus, a central
pleckstrin homology (PH)-like domain, and four
ankyrin-like repeats at the N terminus, is an important
component of focal adhesion complex anchoring actin
filaments to integrin receptors and the cell membrane
[14]. Previous studies have demonstrated that ILK regu-
lates fibroblast migration through the phosphatidylinosi-
tol-3 kinase (PI3K) [15], osteosarcoma cell spreading
and motility via Rho-associated kinase (ROCK) [16], and
mammary epithelial cell migration through the guanine
nucleotide exchange factor a-PIX [17].
There is also growing evidence on the cooperation
between PDGF receptor and integrins in regulating cel-
lular survival and adhesion [18-20]. However, little is
known about the existence of cross-talk between ILK
and PDGF signaling in vascular smooth muscle cells
and the probable regulatory role of ILK during PDGF-
induced SMC migration. In the present study, we have
examined the potential function for ILK as an upstream
protein regulating the migratory response to PDGF in a
primary mouse aortic SMC culture. We have also char-
acterized one downstream pathway that mediates the
regulatory role of ILK in modulation actin polymeriza-
tion and SMC migration.
Results
PDGF activates integrin-linked kinase in mouse
aortic SMCs
To study the effect of PDGF treatment on ILK activa-
tion, mouse aortic SMCs were treated with 25 ng/ml of
PDGF-BB for various timepoints and cell lysates were
collected and subjected to the kinase activity assay. As
shown, PDGF treatment increased ILK kinase activity
around 30 minutes post treatment in the SMC culture
w i t h o u th a v i n ga n ys i g n i f i c a n te f f e c to nt o t a lI L Kp r o -
tein expression. PDGF-induced ILK kinase activity
declined around 60 minutes after treatment (figure 1A).
To ensure the specificity of the test and as a negative
control, a group of SMCs culture was transfected with
specific ILK siRNA for 96 hours. Such treatment
completely abolished ILK protein expression in SMCs
(figure 1B). As shown, very little kinase activity was
detected in ILK-siRNA group confirming that the results
o ft h ek i n a s ea c t i v i t ya s s a yi ss p e c i f i c .I ti sn o t e w o r t h y
that we carefully monitored the morphology of SMCs
transfected with ILK siRNA for the incubation period
prior to PDGF treatment (96 hours) to assure that
siRNA treatment had no cytotoxic effect on mouse
SMC (data not shown).
PDGF induces SMC migration through an
ILK-dependent pathway
To investigate the potential function of ILK in regula-
tion of PDGF-induced SMC migration, cells were trans-
fected with specific ILK siRNA, and then treated with
25 ng/ml of PDGF-BB. The migratory response was
measured using both modified Transwell Boyden cham-
ber and wound healing assays. Inhibition of ILK protein
expression markedly decreased SMC migration indicat-
ing that the presence of ILK was required for transdu-
cing the migratory signal stimulated by PDGF-BB
(figures 2A &2B).
PDGF is considered as a very potent mitogen. The
observed effect of PDGF-BB on wound closure in figure
2B could be due to the effect of this growth factor on
SMC proliferation and/or migration. Thus, to determine
whether the proliferatory effect of PDGF-BB had con-
tributed to the observed increase in cell migration., cells
were treated with increasing doses of PDGF-BB for 24
hours (the maximum time required for wound closure),
and cell proliferation and migration were measured
using the modified Transwell Boyden chamber assay
and MTS cell proliferation assay, respectively. Treat-
ment of primary mouse SMCs with 25 ng/ml of PDGF-
BB significantly increased cell migration without having
any noticeable effect on SMC proliferation. To assure
the accuracy of both assays and as a positive control,
m o u s eS M Cc u l t u r ew e r ea l s ot r e a t e dw i t h1 0 %s e r u m .
These findings emphasized that the observed increase in
cell migration in both assays used in this study (24
hours post injury or following loading onto Transwell
Boyden Chambers) was due to the pro-migratory, not
proliferatory, effect of PDGF-BB on mouse aortic SMC
(additional file 1, figure S1).
ILK inhibition abolishes PDGF-induced p38 MAPK
activation in mouse aortic SMC culture
Studies in various in vitro models, have shown that
members of the family of the mitogen activated protein
kinases (MAPKs) become activated and play a crucial
role in regulating cell migration in response to PDGF
treatment [21-24]. However, the actual mechanisms
underlying this activation and the identity of the
upstream kinases involved are not fully elucidated. Here,
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Page 2 of 12Figure 1 PDGF treatment increases integrin-linked kinase activity in mouse aortic smooth muscle cell culture. A) Primary mouse aortic
SMCs were serum-starved overnight and then treated with 25 ng/ml of PDGF-BB. ILK kinase activity was measured at various timepoints
following treatment. PDGF-BB increased ILK kinase activity (two fold increase). SMC culture transfected with ILK siRNA was used as negative
control in the assay. As shown in first lane of the blot, ILK expression was completely abolished in negative control group that led to a
significant decrease in ILK kinase activity in this group. B) Transfection of mouse aortic SMCs with ILK siRNA for 96 hours completely blocked ILK
protein expression. Data presents three independent experiments and is presented as mean ± STDEV (n = 3), where P < 0.05 was considered
significant.
Figure 2 PDGF induces SMC migration through anILK-dependent pathway. A) Inhibition of ILK protein expression with 20 nM ILK siRNA
markedly decreased SMC migration in response to PDGF-BB. Data represents three independent experiments (n = 3 culture plates in each
replicate) and the value is presented as mean ± STDEV where P < 0.05 was considered significant. B) ILK inhibition decreased the number of
migrated SMCs into the site of injury in response to PDGF-BB treatment as compared to the control group (contorl siRNA). Original
magnification, ×40. Data present one of three independent experiments.
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Page 3 of 12we first characterized the dynamics of MAPKs family
activation in response to PDGF-BB treatment in our pri-
mary mouse aortic SMC model. In agreement with pre-
vious reports in various cell models, PDGF-BB
treatment resulted in the phosphorylation of all three
members of MAPKs family, extracellular signal-regu-
lated protein kinase 1/2 (Erk1/2), Jun N-terminus kinase
(JNK), and p38 MAPK starting around 5 minutes and
with a peak activation at 20-30 minutes post-treatment
(additional file 2, figure S2).
To investigate the role of each member of MAPKs
family in regulating PDGF-induced cell migration, SMCs
were treated with specific MEK/Erk1/2 inhibitor (20 μM
U0126), JNK inhibitor (50 μM SP600125), and p38
MAPK inhibitor (10 μM SB202190) for two hours prior
to PDGF-BB treatment and cell migration was measured
using the modified Transwell Boyden Chamber assay.
Inhibition of all members of MAPKs family markedly
reduced mouse SMC migration in response to PDGF-
BB treatment (figure 3A).
Various components of focal adhesion complex have
been shown to regulate or cross talk with members of
MAPKs family [24]. ILK, as a key constituent of the
focal adhesion complex, also plays an important func-
tion in transducing inside-out and outside-in signals
[25]. To investigate the role of ILK in regulating
MAPKs activation in response to PDGF, SMCs were
transfected with specific ILK siRNA prior to PDGF-BB
treatment. Inhibition of ILK expression with specific
siRNA resulted in significant decrease in PDGF-induced
p38 MAPK phosphorylation (figure 3B), while having no
effect on Erk1/2 and JNK phosphorylation (figure 3C).
This observation suggests that ILK presence is required
for PDGF-induced phosphorylation of p38 MAPK in
mouse SMC.
ILK mediates PDGF-induced mouse aortic SMC migration
through a p38 MAPK-dependent pathway
Taking into account that PDGF-BB activates both ILK
and p38 MAPK in mouse aortic SMCs (figures 1A &
Additional file 1, figure S1), and the observation that
p38 MAPK has a crucial role in PDGF-induced cell
migration (Figure 3A); we sought to determine whether
ILK can also modulate the migratory effect of p38
MAPK activation in response to PDGF-BB. To examine
this hypothesis, we utilized a gain and loss of function
approach using adenoviral constructs of ILK and/or p38
MAPK.
In order to revalidate the important role of p38
MAPK activation during the migratory response, and
also to exploit a more target-specific approach, we first
infected primary mouse SMCs with adenoviral con-
structs expressing either a dominant negative form of
p38 MAPK (Ad-Dn-p38), a wild type form of p38
MAPK (Ad-Wt-p38), or a GFP (Ad-GFP) protein. Wes-
tern blot analysis (measuring protein expression) and
fluorescent microscopy (visualizing GFP expression)
were used to evaluate the transfection efficiency at 36
hours post transfection (Figures 4A &4B).
In concurrence with our previous observations, over-
expression of a dominant negative mutant of p38
MAPK significantly reduced PDGF-induced SMC migra-
tion (Figure 4C). Furthermore, over-expression of a wild
type form of p38 rescued SMC migration in response to
PDGF-BB, corroborating the specificity of p38 MAPK
inhibition in mouse SMC culture transfected with the
Ad-Dn-p38 MAPK construct (Figure 4C).
Moreover, a kinase-deficient form of ILK (E359K),
which is also incapable of binding to paxillin and parvin
and therefore unable to participate in formation of the
focal adhesion complex, resulted in a significant decline
in PDGF-induced SMC migration, an event that can be
reversed by a wild type form of ILK (Figure 5A).
Finally, to establish a cause and effect association
between inhibition of ILK, a downstream decrease in
p38 MAPK phosphorylation, and the subsequent decline
in cell migration, we co-transfected cells with a kinase
deficient form of ILK (E359K) along with an active form
of MKK3/6 (the specific upstream activator of p38
MAPK) or a wild type form of p38 MAPK. As shown,
expression of Ad-Ca-MKK3/6 significantly reversed the
inhibitory effect of ILK inhibition (Ad-Kd-ILK) in
PDGF-treated SMCs (Figure 5B). In contrast, over-
expression of the wild type p38 MAPK in SMCs already
transfected with Ad-Kd-ILK, did not rescue cell migra-
tion, confirming our previous observation that the exis-
tence of an active form of ILK was required to facilitate
the p38 MAPK-mediated migratory response to PDGF-
BB (Figure 5B).
ILK and p38 MAPK regulate PDGF-induced actin
cytoskeleton polymerization in vascular SMC
Actin polymerization and re-organization is a critical
step in cell motility and migration. To characterize the
role of ILK and p38 MAPK in regulating actin polymeri-
zation in response to PDGF, cells were transfected with
specific ILK siRNA (20 nM) or treated with specific p38
MAPK inhibitor (10 μM SB202190) prior to PDGF
treatment. Inhibition of ILK expression and p38 MAPK
activity significantly blocked PDGF-induced actin poly-
merization and re-organization in mouse SMC, indicat-
ing a crucial role for ILK and p38 MAPK in regulation
actin-mediated cell migration (Figures 6A, B).
Discussion
Vascular SMC migration contributes to the intimal
thickening in occlusive vascular diseases. Following vas-
cular injury, SMC migratory response to various stimuli
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Page 4 of 12Figure 3 ILK inhibition abolishes PDGF-induced p38 MAPK activation in mouse aortic SMCs. A) Mouse aortic SMCs were treated with
specific MAPKs inhibitors at specified concentrations for 2 hours prior to seeding onto Transwell Boyden Chambers and PDGF-BB treatment (25
ng/ml) and during the incubation period (12 hours), and cell migration was measured at 12 hours post culture. As shown, inhibition of all three
members of MAPKs family significantly reduced SMC migration in response to PDGF-BB. Data is the representative of three independent
experiments (n = 3 cell culture replicates for each experiments). B) Mouse aortic SMCs were transfected with 20 nM of specific ILK siRNA and
then treated with 25 ng/ml of PDGF-BB for specified timepoints. Inhibition of ILK protein expression markedly reduced PDGF-induced p38 MAPK
phosphorylation in mouse aortic SMCs. The blot presents one of three independent experiments. The value in the graph is presented as the
mean ± STDEV of three independent experiments. C) ILK inhibition by specific siRNA had no detectable effect on Erk1/2 and JNK
phosphorylation in response to PDGF-BB treatment in mouse aortic SMC culture. Data presents one of three independent experiments (n = 3
cell cultures for each independent experiments).
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Page 5 of 12begins with activation of cell surface receptors followed
by remodeling events that involve focal adhesion com-
plex and filament actin remodeling. Various cytokines,
peptide growth factors, and components of the extracel-
lular matrix (ECM) have been characterized as pro-
migratory molecules.
PDGF is a very potent stimulant for SMC migration
through activation of several signaling pathways [26-28].
In vascular SMC, PDGF activates multiple signaling
cascades including the PI3K/Akt, protein kinase A
(PKA), Src, Ras, and MAPKs signaling. The family of
MAPKs comprises three distinct protein kinases, p38
MAPK, JNK, and Erk1/2, all of which have been shown
to be involved in vascular diseases and remodeling [23].
On another note, integrin clustering and its down-
stream signals are necessary for SMC adhesion to ECM,
an event that also initiates pro-migratory responses
within the vascular wall. Mawatari and colleagues have
Figure 4 Dominant negative form of p38 MAPK significantly decreases SMC migration in response to PDGF. A) Photomicrograph of
mouse aortic SMCs showing the morphology and GFP expression at 36 hours following transfection. Sub-confluent SMCs were infected with
adenoviral vector at the multiplicity of infection of 100. Note the high level of GFP expression as well as the normal phenotype of Ad-GFP-
transfected SMCs. Original magnification, ×200. B) Over-expression of a dominant negative form of p38 MAPK markedly increased total p38
MAPK expression while blocking p38 MAPK phosphorylation in response to serum treatment in SMCs (serum is used as a strong activator for
p38 MAPK). Also, note the considerable increase in ILK expression level in SMCs transfected with adenoviral ILK constructs. C) For migration
assay, transfected SMCs were cultured in Transwell Boyden Chambers in the presence or absence of 25 ng/ml of PDGF-BB and cell migration
was measured 12 hours post culture. Dominant negative p38 MAPK significantly decreases SMC migration in response to PDGF-BB treatment
while expression of a wild type form of p38 MAPK increases SMC migration in response to PDGF-BB. In addition, over-expression of a wild type
mutant of p38 MAPK subverted the inhibitory effect of p38 inhibition on SMC migration. Data represents three independent experiments (n = 3
cell cultures for each independent experiments).
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integrin is required for growth factor and cytokine-
induced proliferation [29]. It is believed that a coordi-
nated cross-talk between integrins and growth factor
tyrosine kinase receptors is necessary for the effective
modulation of cell survival, growth, proliferation, and
migration [30].
ILK is a key protein of focal adhesion complex con-
necting b1a n db3 integrins in plasma membrane to the
actin cytoskeletal machinery. ILK also interacts with
growth factor receptors through the NH2-terminal
ankyrin repeat domain and small GTPase signaling
molecules such as Nck-2 [14,31]. Previous reports on
the effect of PDGF on ILK expression and activity in
non-muscle cell cultures were controversial. While
Campana et al reported on a PDGF-induced increase in
ILK activity in primary rat Schwann cells [32], Janji and
colleagues proposed that PDGF had no effect on ILK
expression in melanoma HT-144 cells [33], indicating
that the outcome of PDGF treatment on ILK signaling
is cell specific.
In the present study, we have shown that PDGF-BB
treatment results in an increase in ILK kinase activity in
mouse aortic SMC culture. It is of importance that the
increase in ILK kinase activity in SMCs is associated
w i t hac o n s i d e r a b l ei n c r e a s ei ne x p r e s s i o no fb o t hb1
and b3 integrins (Esfandiarei & van Breemen, unpub-
lished observation). It is well known that the adhesive
function of integrin receptors affects cytoskeleton rear-
rangement and cell motility. Therefore, it is presumable
that increase in b1a n db3 integrins expression contri-
butes to the pro-migratory effect of PDGF-BB in SMC
culture. However, further investigation is required to
evaluate the potential cross-talk between b1a n db3
integrins and PDGF receptors and the significance of
such events in vascular SMC migration.
Numerous studies have provided a wealth of informa-
tion on the crucial regulatory role for ILK as a protein
Figure 5 ILK regulates PDGF-induced SMC migration through a p38 MAPK-dependent pathway. A) Kinase deficient mutant of ILK
significantly reduced PDGF-induced SMC migration in a Traswell Boyden Chamber migration assay. As shown, expression of a wild type form of
ILK rescued SMC migratory response indicating the specificity of ILK inhibition by the adenoviral construct. B) Over-expression of an active form
of MKK3/MKK6 (specific upstream activators of p38 MAPK), but not a wild type form of p38 MAPK, rescued SMC migration in response to PDGF-
BB indicating that an active form of ILK is required for the initiation of a p38 MAPK-dependent migratory response to PDGF-BB in mouse aortic
SMCs. (n = 3 cell cultures for each independent experiments).
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Page 7 of 12kinase and also as a molecular scaffold and adaptor pro-
tein during cell spreading and migration in a variety of
cancer cells [13,34]. Moreover, A recent study has
shown that an increase in ILK expression coincides with
higher rate of SMC migration within the atherosclerotic
plaque in ApoE -/- mice, a reliable model that mimics
the progression of atherosclerosis in humans [35]. On
the contrary, Ho et al has shown that following balloon
catheter injury of the rat carotid artery, a significant
decrease in ILK expression is associated with an eleva-
tion in vascular SMC proliferation and migration [36].
Nevertheless, there is no clear understanding as to how
ILK contributes to the intimal thickening in response to
growth factors and cytokines released during the devel-
opment of the atherosclerotic plaque, and the mechan-
isms by which ILK may modulate vascular SMC
migration to the sub-intimal layer of the vascular wall.
In this study, we examined the role of ILK in cell
migration, by inhibiting (using siRNA) or increasing
(using an adenoviral vector expressing wild type ILK)
ILK expression. Inhibition of ILK by different means
significantly decreased cell migration in response to
Figure 6 ILK and p38 MAPK regulate PDGF-induced actin cytoskeleton polymerization in vascular SMCs. A) Mouse SMCs were treated
with either vehicle (DMSO) or with 10 μM of p38 MAPK specific inhibitor SB202190 for 1 hour prior to PDGF treatment. Following treatment,
cells were washed and fixed and then stained for actin filaments. Inhibition of p38 MAPK markedly blocks PDGF-induced actin polymerization
and reorganization (original magnification ×400). B) Mouse aortic SMCs were transfected with 20 nM of specific ILK siRNA and then treated with
25 ng/ml of PDGF-BB for 20 minutes. Cells were then fixed and stained for actin filaments. Inhibition of ILK expression in SMCs significantly
reduced PDGF-induced actin polymerization and reorganization in mouse aortic SMCs. Images are representative image of three independent
experiments (original magnification ×400).
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Page 8 of 12PDGF-BB, demonstrating that ILK plays an important
role in regulating PDGF-induced vascular SMC migra-
tion. Expression of a wild type form of ILK increased
SMC migration even in the absence of growth factor. It
is noteworthy that the effect of wild type ILK in increas-
ing SMC migration is more evident when SMCs were
treated with PDGF-BB (figure 6A). These observations
are in agreement with previous report by Dwivedi et al
[37] that over-expression of a dominant negative form
of ILK markedly reduced intimal thickening in human
saphenous vein organ culture.
ILK mutation within the catalytic domain (E359K) dis-
rupts the interaction and binding of ILK with two
important components of focal adhesion complex, b-
parvin and paxillin. This interaction is required for the
assembly of a functional focal adhesion complex and
subsequent actin polymerization and reorganization
[38,39]. Over-expression of the E395K mutant of ILK
resulted in significant reduction in PDGF-induced SMC
migration. The effect was fully reversed by a wild type
form of ILK. These findings further underscore the cru-
cial function of ILK as molecular scaffold during SMC
migration.
In an effort to understand how ILK mediates the pro-
migratory effect of PDGF-BB in primary mouse SMC
using RNA silencing technique, we were able to show
that ILK inhibition could lead to a considerable decrease
in p38 MAPK phosphorylation, while having no visible
effect on Erk1/2 and JNK phosphorylation in response
to PDGF-BB treatment. We also demonstrated that
over-expression of an active form of MKK3/6 (specific
upstream activator of p38 MAPK) dramatically reversed
the inhibitory effect of ILK inhibition on SMC migra-
tion. Expression of a wild type form of p38 MAPK
markedly increased SMC migration in the presence of
PDGF-BB; however, it could not restore migratory
response in cells over-expressing a kinase deficient form
of ILK. It is of importance that the latter observation
accentuates the view that the presence of a functional
ILK is required for the initiation of a p38 MAPK-depen-
d e n tm i g r a t o r yr e s p o n s et oP D G F - B Bi nm o u s ea o r t i c
SMCs. Further studies are required to characterize the
precise mechanisms underlying the ILK-mediated regu-
lation of p38 MAPK in SMCs.
Actin polymerization and reorganization is a crucial
step in cell migration. We have shown that PDGF
increases actin polymerization and filament reorganiza-
t i o ni nS M C s .T h i se v e n tw a ss i g n i f i c a n t l yb l o c k e db y
both ILK siRNA and p38 MAPK inhibitor, confirming
the importance of this pathway in regulating SMC
migration. The actual mechanism by which p38 MAPK
may regulate cell migration is not well understood.
Actin polymerization and reorganization is under rigor-
ous regulation by a group of protein kinases and/or
phosphatases that coordinate the constant turnover of
actin filaments in a stimulated cell. Among these, cofilin
is a conserved actin-binding protein that enhances actin
filament reorganization through de-polymerization and
severing of preexisting actin filaments [40]. It is well
known that phosphorylation of cofilin (serine 3) by LIM
kinase (LIMK) and testicular protein kinase 2 (TESK-2)
results in deactivation of cofilin and subsequent inhibi-
tion of actin reorganization [41,42]. In mouse aortic
SMCs, PDGF treatment resulted in rapid de-phosphory-
lation and activation of cofilin around 5-15 minutes
post-treatment (additional file 3, figure S3). PDGF also
increased LIMK phosphorylation leading to phosphory-
lation and deactivation of cofilin (additional file 3, figure
S3). The feedback mechanism provides a strict control
system for cell responses to migratory stimuli such as
PDGF. Our preliminary observation suggests that p38
MAPK may control actin reorganization partly via regu-
lating the de-phosphorylation and consequent activation
of cofilin (Esfandiarei & van Breemen, unpublished
observation). Further detailed studies are ongoing in our
laboratory to characterize the signaling network and
downstream pathways mediating such regulatory events.
Conclusion
In summary, we have provided evidence that ILK is an
important regulator of mouse vascular smooth muscle
cell migration in response to PDGF-BB by modulating
p38 MAPK phosphorylation. To our knowledge, this is
the first report of the regulation of p38 MAPK by integ-
rin signaling in mediating platelet-derived growth fac-
tor-induced migration in vascular smooth muscles.
Future in vivo studies using specific small molecule inhi-
bitors for ILK and/or p38 MAPK as well as developing
transgenic animal models will provide additional infor-
mation on the potential therapeutic value of integrin
signaling, in general, and the integrin-linked kinase, in
particular, in controlling vascular smooth muscle cell
migration during the progression of occlusive vascular
diseases.
Methods
Preparation of Primary SMC Culture
All surgical procedures and animal care were conducted
according to the Guidelines for Animal Experiments of
Faculty of Medicine, University of British Columbia
approved by the University Committee on Ethics of Ani-
mal Experiments. Primary mouse aortic SMCs were iso-
lated as described previously [43]. Breifly, aortic
segments were isolated, cleaned of excess advential tis-
sue, and digested using collagenase II (0.5 mg/ml). Iso-
lated cells were pelleted, resuspended, and grown in
Dulbecco’s modified Eagle’s medium. Sub-confluent (60-
80%) cutlures were used for all experiments. ILK
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Page 9 of 12recombinant adenoviral constructs were kind gifts from
Dr. Hyo-Soo Kim (Seoul National University Hospital,
Korea). Adenoviral constructs for recombinant p38
MAPK and constitutively active forms of MKK3/6 were
kindly provided by Dr. Donald R. Menick (Medical Uni-
versity of South Carolina, USA).
Transient Transfection
For transient transfection experiments, cells were
infected with adenoviruses encoding dominant negative
p38 MAPK (Ad-Dn-p38), wild type of p38 MAPK (Ad-
Wt-p38), constitutively active MKK3/6 (Ad-Ca-MKK3/
6), kinase-deficient ILK (Ad-Kd-ILK), or wild type ILK
(Ad-Wt-ILK) with multiplicity of infection of 100
(MOI = 100). Following overnight incubation at 37°C,
SMCs were replenished with fresh medium. Transfec-
tion efficiency was measured by fluorescence microscopy
and Western blot analysis at 36 hours post transfection.
For all experiments, transfected SMCs were used at
36 hours post transfection. For ILK RNA inhibition
experiments, SMCs were transfected with 20 nM of a
21-base pair double-stranded small interfering RNA
(siRNA) molecule targeting the PH domain of ILK or a
control nonspecific siRNA. ILK siRNA was introduced
to cells using 2.5 μl of siLentFect Transfection Reagent
according to the manufacturer’sp r o t o c o l( B i o - R a d
Laboratories, Mississauga, ON, Canada). Twenty four
hours post-transfection cells were replenished with fresh
serum-containing medium, incubated for 96 hours, and
then used for various experiments. ILK silencing was
determined by Western blot of transfected lysates with
an anti-ILK antibody.
Western Blot Analysis
Cells either untreated or treated with various experi-
mental reagents were washed twice with ice-cold PBS,
and kept on ice for 15 min in lysis buffer containing 50
mM pyrophosphate, 50 mM, NaF, 50 mM NaCl, 5 mM
EDTA, 5 mM EGTA, 100 μMN a 3VO4, 10 mM HEPES
(pH 7.4), 0.1% Triton X-100, 10 μg/ml leupeptin, and 1
mM phenylmethylsulfonyl fluoride. Cell lysates were col-
lected by scraping and protein concentration was deter-
mined using Bradford assay. Extracted protein (40-80
μg) was fractionated by electrophoresis in 7% to 9%
sodium dodecyl sulfate-polyacrylamide gels, transferred
to nitrocellulose membranes, and blocked with PBS con-
taining 0.1% Tween-20 and 5% non-fat dry milk for
1 hour. Afterward, the membrane was incubated with
specific primary antibody overnight at 4°C, followed by
secondary antibody for one hour at room temperature.
Immunoblots were visualized with an enhanced chemi-
luminescence detection system according to the pro-
tocol of the manufacturer (Pierce Biotechnology,
R o c k f o r d ,I L ,U S A ) .D e n s i t o m e t r ya n a l y s i sw a s
performed by using the National Institutes of Health
ImageJ software (version 1.27z). Density values for pro-
teins were normalized to the level for control groups
(arbitrarily set to 1.0-fold).
ILK Kinase Assay
Kinase assay was performed using 250 μgo fp r o t e i n
lysates immunoprecipitated with 5 μg ILK antibody and
protein A Sepharose beads overnight at 4°C, while shak-
ing. The immunocomplex was washed twice with high
salt NP-40 lysis buffer (containing 750 mM NaCl), and
then three times with wash buffer containing 50 mM
HEPES pH 7.5, 85 mM KCl, 10 mM ethyleneglycol tetra-
acetate (EGTA), 0.1% Tween 80, 1 mM Na3VO4,1 0m M
Mg2Cl. The kinase assay was performed in the reaction
buffer containing 0.5 μg ATP (250 μMA T Pa n d5μCi
[g -
32P] ATP) and 5 μg of myelin basic protein (MBP) as
substrate at 30°C for 20 minutes in a shaker-incubator.
Samples were fractionated by electrophoresis in a 12%
sodium dodecyl sulfate-polyacrylamide gel, and phos-
phorylation of substrate by ILK was measured by a scin-
tillation counter autoradiography.
Cell Migration Assay
Cell migration was measured using QCM™ Transwell
Colorimetric Cell Migration Assay according to the
manufacturer’s protocol (Chemicon International,
T e m e c u l a ,C A ,U S A ) .B r i e f l y ,1×1 0
5 serum-starved
SMCs were loaded onto the upper well of the chamber
i nt h ep r e s e n c eo ra b s e n c eo fi n h i b i t o r sw h i l el o w e r
wells were filled with culture medium with or without
PDGF-BB (25 ng/ml). Following 12 hours incubation,
non-migrating cells on the upper side of membranes
were removed by wiping and rinsing, and migrated cells
were counted using colorimetric assay. Data are repre-
sented as fold change in cell migration where migratory
rates for control groups are arbitrarily set to 1.0 fold.
Wound Healing Assay
Sub-confluent transfected or non-transfected SMCs
were grown on glass coverslips. Following overnight
serum starvation, cell cultures were scratched with a
sterile pipette tip to form a wound, washed with pre-
warmed sterile PBS, and incubated with medium in the
presence or absence of inhibitors for 18-24 hours. At
desired timepoints post injury cells were fixed and sub-
jected to imaging using Nikon inverted microscope and
Spot digital camera.
Cell Viability Assay
Sub-confluent SMCs were plated in a 24-well culture
plate and treated with various doses of PDGF for 24
hours. The CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay (MTS) was used to measure cell
Esfandiarei et al. BMC Cell Biology 2010, 11:16
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mega, Madison, WI).
Actin Cytoskeleton Staining
Cells were grown on glass slides and subjected to var-
ious treatments. At desired timepoints cells were fixed
(3.7% formaldehyde for 15 min & 70% ethanol for 2
min). Following permeabiliza t i o ni n0 . 1 %T r i t o nX - 1 0 0 ,
cells were incubated with AlexaFluor 488-labelled phal-
loidin (Molecular Probes, Invitrogen Detection Technol-
ogies) for 1 hour in room temparature. Glass slides were
mounted and sealed using ProLong® Gold anti-fade
reagent (Molecular Probes, Invitrogen Detection Tech-
nologies), and then imaged with Olmpus inverted
microscope and Spot digital camera.
Statistical Analysis
Two-way analysis of variance (ANOVA) with multiple
comparisons andpaired Student’s t tests were performed.
Values shown are the mean ± standard deviation. A
value of P < 0.05 was considered significant.
Additional file 1: Figure 1S. Effect of PDGF treatment on mouse
aortic SMCs migration and proliferation. Mouse SMCs were treated
with increasing doses of PDGF-BB for 24 hours and cell migration and
proliferation were measured. Cells treated with 10% serum were used as
the positive control. As shown, 25 ng/ml of PDGF-BB significantly
increased SMCs migration (3 fold increase) with no effect on cell
proliferation indicating that the observed increase in cell migration is not
due to the proliferatory effect of PDGF-BB in SMC culture. Data is
representative of three independent experiments (n = 3 of each culture
condition).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-
16-S1.PDF]
Additional file 2: Figure 2S. Kinetics of MAPKs activation in mouse
aortic SMC culture. PDGF-BB treatment resulted in phosphorylation and
activation of all three members of MAPKs family in mouse aortic SMCs.
Data represents three independent experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-
16-S2.PDF]
Additional file 3: Figure 3S. PDGF induces LIMK and cofilin
phosphorylation in mouse aortic SMCs. Aortic SMCs were serum
starved overnight and then treated with 25 ng/ml of PDGF-BB. Cell
lysates were collected in various timepoints and phosphorylation of LIMK
and cofilin was measured. Data represents three independent
experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-
16-S3.PDF]
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